Development Of In Vitro Systems To Study Endocrine Disruptors
Abstract
Environmental estrogenic endocrine disruptors (EDs) are a health concern as the general population is exposed to a variety of EDs at low doses. Rapid screening and in depth understanding of how the body responds to EDs and their mixtures are crucial for toxicological evaluation and health protection. In this work, in vitro systems, including stable cells lines with estrogen induced green fluorescence protein (GFP) expression and micro cell culture analog (microCCA) devices, were developed to study EDs. A dual cell-line GFP expression system was constructed to study EDs with activities as estrogen receptor agonists or antagonists. The two stable cell lines, Ishikawa-GFP (uterine origin) and MCF7-GFP (breast origin), displayed increased intracellular GFP intensity with estrogens. This system also responded in a tissue specific manner to selective estrogen receptor modulators, raloxifene and tamoxifen. Our results also suggested no low dose synergistic effects between the tested estrogenic compounds. Physiologically realistic microCCA devices were developed to help predict in vivo responses to EDs. The silicon microCCA device contained a co-culture of three cell lines: MCF7-GFP, Ishikawa-GFP and HepG2/C3A (liver origin). Recirculation of medium mimicked the time dependent changes in drug concentrations and the microfluidic shear conditions inside a body. An in-line bubble trap was incorporated into the system to overcome air bubble related device failure. Interactions between…
How strong is the evidence?
Evidence Hub reads this as a thesis, done in cell cultures (in vitro), not in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.